Financial Performance Summary
Sumitomo Chemical India Limited (SCIL) reported strong financial results for FY 2025-26 with record profitability. Standalone revenue from operations grew 3.1% to ₹31,857.62 million, while net profit increased 8.2% to ₹5,431.39 million. The company achieved its highest-ever EBITDA margin of 20.7% and net profit margin of 16.8%. Consolidated performance was similarly robust with revenue of ₹32,088.87 million and net profit of ₹5,429.75 million.
Dividend and Capital Structure
The Board recommended a final dividend of ₹1.30 per equity share (13%), maintaining the company's consistent dividend distribution policy. SCIL maintained a strong debt-free balance sheet with total assets of ₹44,341.10 million and equity of ₹33,841.84 million. The company held ₹8,815.60 million in current investments and ₹675.29 million in cash, demonstrating robust liquidity with a current ratio of 3.48x.
Leadership and Governance Changes
Significant leadership transitions were proposed effective September 2026, with Dr Suresh Ramachandran promoted from Deputy Managing Director to Managing Director, and Mr Chetan Shah transitioning to a Non-Executive role. The Board also proposed appointments of Mr Anand Mohan Tiwari as Independent Director and reappointment of Mr N Sivaraman. The 26th AGM is scheduled for July 27, 2026, to approve these changes and related party transactions.
Operational and Business Highlights
Domestic sales increased to ₹24,847.32 million while exports decreased marginally to ₹6,707.32 million. Branded formulations constituted 81% of domestic sales, with specialty portfolio接近 30% of revenues. The company successfully launched 7 new products including Excalia Max® and Lentigo, with 4 additional patented products expected in FY27. Manufacturing expansion continued with a ₹150 crore greenfield project at Dahej, Gujarat.
Related Party Transactions and Royalty
The company sought approval for material related party transactions with Sumitomo Chemical Company, Limited (holding company) totaling ₹16,235 million for FY27. This includes purchase/sale of goods, services, and royalty payments of 3% of net sales on selected products for trademark and technology know-how.
Audit and Regulatory Compliance
Auditors B S R & Co. LLP issued an unqualified opinion confirming adequate internal financial controls and no fraud detected. The company complied with all SEBI Listing Regulations, though minor penalties were imposed for delay in filling Independent Director vacancies. Contingent liabilities totaled ₹600.73 million, primarily comprising tax matters and consumer claims.
Risk Factors and Outlook
The company faces challenges from below-normal monsoon forecasts (92% of LPA), El Niño conditions affecting agricultural output, regulatory constraints on biostimulants, and currency volatility. However, SCIL's strong financial position, expanding product portfolio, and strategic investments position it well for sustained growth despite market headwinds.
Sustainability and CSR Initiatives
SCIL maintained strong environmental credentials with 26% renewable energy consumption and recycled 3,027 MT plastic waste. CSR expenditure of ₹123.98 million exceeded the mandated 2%, benefiting 35,000+ students through education initiatives and 40,000+ beneficiaries through healthcare programs.